STAT3 and lung adenocarcinoma: In contrast to other studies, the expression of Ki67, STAT3 and MAPK in skin did not show a relationship with adequate treatment response with EGFR inhibitors related to progression‐free survival in patients with stage IV lung adenocarcinoma.